Provention Bio's novel diabetes treatment
Under looked biotech company might be near tipping point
Alcides is a Cell Bio graduate, finishing a PhD in Neuroscience. Writes about life sciences, pharma, and biotech.
2020-08-27 10:09

Provention Bio Inc (NASDAQ: PRVB) is a small cap clinical-stage biotech ($740M market cap) focused on the development of treatments for immunological diseases such as type 1 diabetes (T1D),and celiac disease. Since their IPO in July 2018, PRVB stock value has increased by over 640%. Currently trading at the low tens, data on a novel drug treatment for diabetes shows it could be a big winner for the New Jersey company and its investors.

Provention Bio's novel diabetes treatment

Autoimmune diseases are on the rise in the US: over 15 million people in the US suffer from at least one condition affecting their immune system. One of these diseases is T1D, which results from the pancreas failing to produce the necessary amount of insulin for normal sugar regulation. Previously referred to as “insulin-dependent diabetes mellitus”, T1D is caused by loss of pancreatic beta cells due to an autoimmune response. The American Diabetes Association estimates that 40,000 patients are diagnosed with T1D each year in the US.

In genetically susceptible persons, T1D progresses through asymptomatic stages before the development of overt hyperglycemia. Before the onset of insulin dependence in T1D, disease management aims to delay the onset as well as stimulate insulin production by the patient. Teplizumab is a drug in the PRVB pipeline marketed for delay or prevention of insulin-dependent T1D.

Teplizumab could become a home-run for PRVB, and its investors

In a paper published last year in the New England Journal of Medicine, researchers at PRVB showed quite encouraging results for a Phase 2 randomized trial of Teplizumab. When compared to the control group, a single 14-day outpatient course of Teplizumab was able to delay the onset of insulin-dependence for an average of 2 years. Meaning that a patient recently diagnosed with T1D could double the amount of time left in the course of the disease until they completely stop producing any insulin, thus requiring daily administration of the hormone. Let’s remember that T1D results in lifetime use of insulin and other drugs as the disease progresses.

Interestingly, the trial data for Teplizumab, also shows the presence of “super-responders”. This group of patients, after a single course of the treatment, have seen a delay in insulin-dependence onset of up to 8 years (when the follow-up occurred).

Teplizumab, which should be approved by FDA beginning 2021, is currently in the step of completing BLA filing before Q4 2020 for at-risk patients. Their very promising results for Phase 2 allowed them to get designated as a breakthrough treatment by FDA, thus their decision to pursue approval. In parallel, Phase 3 trials are finishing recruitment as a treatment for newly diagnosed T1D patients. PRVB is also exploring the opportunities of authorization for use of Teplizumab as a topical drug, as well as its efficacy in treating psoriatic arthritis, and other autoimmune diseases.

Expected to launch mid 2021, Teplizumab could be the tipping point for PRVB. Having no approved products means PRVB is not generating any revenue. In fact their Q1 2020 results moved them to raise money by selling shares of its common stock. This “follow-on” brought in $100M in additional cash for Q2 2020 which should prevent any further dilutions soon.


PRVB has developed Teplizumab, a novel treatment for diabetes. Phase 2 trials show outstanding results and the possibility to address an unmet need within a growing market. The drug can be marketed more broadly in autoimmune disease care. If you’ve ever noticed how volatile the biotech market is, then this might be a good opportunity to jump in the action.

Disclaimer: I have no positions in any of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article. All information should be independently verified and should not be relied upon for purposes of transacting securities or other investments. See terms for more info.

Rate this article

Published On
2020-08-27 10:09

About the Author
Alcides is a Cell Bio graduate, finishing a PhD in Neuroscience. Writes about life sciences, pharma, and biotech.

You've read 1 article in the last year
..thank you for supporting us and for visiting our site. Unlike many other sites, The Dog of Wall Street is available for everyone to read. Our focus is to provide great content for free. Do you like what we are doing? Buy us a cup coffee. It is the fuel that keeps us going..

AI-mazing returns: The top 3 AI stocks to invest in now!
Don't miss out on the opportunity to invest in these cutting-edge companies and be a part of the future of AI.
By Staff | 2 weeks ago

Goldman Sachs Trims the Fat with 3,200 Job Cuts
Goldman Sachs is cutting approximately 3,200 jobs from its core banking and trading units.
By Staff | 4 weeks ago

Tilray Q2 Earnings Leave Investors Wanting More
While Tilray has maintained its leading market share in the recreational cannabis market in Canada and the medical cannabis market in Europe, its Q2 earnings, which included a loss per share of -$0.11 and an adjusted loss per share of -$0.06, have left investors questioning the company's future growth prospects.
By Staff | 4 weeks ago

Qualcomm's partnership with Iridium takes connectivity to new heights
Qualcomm's partnership with Iridium brings satellite-based messaging technology to phones, laptops and other devices, providing new opportunities for connectivity in any location.
By Staff | 4 weeks ago

Hologic's Fiscal Q1 2023 Earnings: A Ray of Hope in a Stormy Year
Hologic has managed to achieve impressive financial results in Fiscal Q1 2023.
By Staff | 4 weeks ago

Why Small and Mid-Cap Stocks Deserve Your Attention
Why valuations make small and mid-cap stocks an attractive option in a potential recession.
By Staff | 4 weeks ago

Get Ready for a Bumpy Year
Despite strong job creation numbers, deeper issues lurk beneath the surface as the Federal Reserve's rate hikes and high inflation threaten to derail the economy.
By Staff | 4 weeks ago